HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

Company Hansoh Pharmaceutical Group Company Limited

3692

KYG549581067

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 06:55:25 17/07/2026 BST			5-day change	1st Jan Change
31.72 ^HKD	-4.34%		-0.75%	-12.14%

07-14	Avery Therapeutics, Inc. announced that it has received $320 million in funding from a group of investors	CI
07-13	Avere Therapeutics, Inc. announced that it expects to receive $69 million in funding from a group of investors	CI

Business description: Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Ltd is an investment holding company primarily engaged in the research and development, production and sale of a series of pharmaceutical products. The Companyâ€™s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Companyâ€™s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The Company mainly conducts its business in the domestic market.

Number of employees: 9,347

Sales by Activity: Hansoh Pharmaceutical Group Company Limited

Fiscal Period: December	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)	2025 (CNY)
Sales of Pharmaceutical Products	9.94B	9.38B	10.1B	12.26B	15.03B

See all business segments

Geographical breakdown of sales: Hansoh Pharmaceutical Group Company Limited

Fiscal Period: December	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)	2025 (CNY)
Mainland China	9.94B	9.38B	10.1B	12.26B	15.03B

See all geographic segments

Executive Committee: Hansoh Pharmaceutical Group Company Limited

Manager	Title	Age	Since
Hui Juan Zhong CEO	Chief Executive Officer	65	01/12/2015
Min Hu DFI	Director of Finance/CFO	49	31/08/2019
Shan Jiang CTO	Chief Tech/Sci/R&D Officer	56	31/07/2024
Xiao Qing Zhang CTO	Chief Tech/Sci/R&D Officer	52	29/02/2024
Chih-Hung Lee CTO	Chief Tech/Sci/R&D Officer	66	31/03/2022

See HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED governance

Composition of the Board of Directors: Hansoh Pharmaceutical Group Company Limited

Director	Title	Age	Since
Hui Juan Zhong CHM	Chairman	65	01/12/2015
Ai Feng Lyu BRD	Director/Board Member	49	10/03/2016
Yu An Sun BRD	Director/Board Member	39	01/12/2015
Guo Qiang Lin BRD	Director/Board Member	83	30/05/2019
Sheung Wai Chan BRD	Director/Board Member	72	30/05/2019
Dong Tao Yang BRD	Director/Board Member	68	30/05/2019
Jia Yan BRD	Director/Board Member	54	25/12/2025

Composition of the Board of Directors

Shareholders: Hansoh Pharmaceutical Group Company Limited

Name	Stocks	%	Valuation
Yu An Sun 64.35 %	3,902,214,583	64.35 %	14 739 M $
Jun Da Cen 15.17 %	920,000,000	15.17 %	3 475 M $
Fidelity Management & Research (Hong Kong) Ltd. 0.6448 %	39,100,000	0.6448 %	148 M $
Yinhua Fund Management Co., Ltd. 0.2908 %	17,632,000	0.2908 %	67 M $
China Asset Management Co., Ltd. 0.1815 %	11,008,000	0.1815 %	42 M $

List of HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED shareholders

Company details: Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Co., Ltd.

287 Xiangke Road

201210, Shanghai

http://www.hspharm.com

address Hansoh Pharmaceutical Group Company Limited(3692)

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED	-4.34%	-0.75%	-8.12%	+152.79%	25.65B
ELI LILLY AND COMPANY	+1.08%	-3.93%	+48.03%	+160.13%	1,043B
JOHNSON & JOHNSON	+1.19%	-3.52%	+51.70%	+56.36%	602B
ABBVIE INC.	+4.21%	+1.79%	+33.48%	+87.04%	449B
ROCHE HOLDING AG	+0.42%	-1.16%	+29.43%	+22.27%	327B
NOVARTIS AG	+1.03%	-0.84%	+29.58%	+45.08%	279B
ASTRAZENECA PLC	+0.49%	-5.44%	+21.00%	+22.32%	264B
AMGEN INC.	+3.70%	+2.19%	+24.27%	+63.38%	201B
GILEAD SCIENCES, INC.	+3.49%	+1.08%	+24.08%	+76.58%	169B
PFIZER INC.	+1.29%	+3.67%	+2.15%	-30.78%	143B
Average	+0.98%	+0.03%	+25.56%	+65.52%	350.27B
Weighted average by Cap.	+1.63%	-1.76%	+36.75%	+83.06%